To test whether an exonuclease point mutation drives clinical antimalarial resistance, the field asked whether E415G in PF3D7_0204800 is causal for piperaquine resistance rather than merely associated.
Evidence CRISPR-Cas9 allelic exchange to introduce E415G in P. falciparum B5, with IC90, PPQ survival, ring-stage survival, and growth assays
- Does not exclude a contributory role of E415G in a resistance background with other mutations
- Effect on parasite fitness only modestly assessed
- Does not address the protein's normal enzymatic function